Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Flunisolide

FDA-approved product (spray, metered, nasal), marketed as Aerobid, Aerospan Hfa, Flunisolide and 2 more.

Registered studies
6
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Flunisolide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Asthma
  • Nasal congestion
  • Rhinitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids; Glucocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis38.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

6registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Flunisolide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Flunisolide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of Physiotherapy in Hospitalized COPD Patients

    NCT02509299 · start 2019-09-01

    Registered record
    Registry ID
    NCT02509299
    Conditions
    COPD
    Interventions
    Physiotherapy program 1; Physiotherapy program 2; Standard medical treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-09-01
    Completion
    2019-12-14
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD
    InterventionPhysiotherapy program 1; Physiotherapy program 2; Standard medical treatment
    PhaseNot applicable
    Registry statusCompleted

  • Physiotherapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

    NCT02515318 · start 2015-09

    Registered record
    Registry ID
    NCT02515318
    Conditions
    COPD
    Interventions
    Physiotherapy program; Medical standard treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2015-09
    Completion
    2018-07
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD
    InterventionPhysiotherapy program; Medical standard treatment
    PhaseNot applicable
    Registry statusUnknown

  • Flunisolide HFA in Children With Small Airway Disease

    NCT02404103 · start 2015-03

    Registered record
    Registry ID
    NCT02404103
    Conditions
    Childhood Asthma
    Interventions
    Flunisolide HFA
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-03
    Completion
    2017-06
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildhood Asthma
    InterventionFlunisolide HFA
    PhaseNot applicable
    Registry statusCompleted

  • Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy

    NCT01347060 · start 2009-07

    Registered record
    Registry ID
    NCT01347060
    Conditions
    Asthma
    Interventions
    fluticasone propionate/salmeterol xinafoate combination; inhaled corticosteroids
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-07
    Completion
    2010-04
    Enrolment
    17,448

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    Interventionfluticasone propionate/salmeterol xinafoate combination; inhaled corticosteroids
    PhaseNot recorded
    Registry statusCompleted

  • Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)

    NCT00346775 · start 2006-05-01

    Registered record
    Registry ID
    NCT00346775
    Conditions
    Rhinitis, Allergic, Perennial
    Interventions
    Beclomethasone dipropionate; Flunisolide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-05-01
    Completion
    2006-06-29
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial
    InterventionBeclomethasone dipropionate; Flunisolide
    PhasePhase 3
    Registry statusCompleted

  • Mentored Patient-Oriented Research Career Development Award

    NCT00203684

    Registered record
    Registry ID
    NCT00203684
    Conditions
    Asthma; Distal Lung Inflammation
    Interventions
    Flunisolide-HFA; Flunisolide-CFC
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma; Distal Lung Inflammation
    InterventionFlunisolide-HFA; Flunisolide-CFC
    PhasePhase 1
    Registry statusCompleted